Article

High Density Lipoprotein Cholesterol-The Next Battle Front in the Fight Against Heart Disease

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Average (ratings)
No ratings
Your rating
Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Many patients on statin therapy understandably develop a false sense of security. They enjoy a lowered level of low-desity lipoprotein (LDL) and a risk reduction of some 35%. However, two out of three patients develop a myocardial infarction (MI) while on a statin therapy. Statins often do not increase HDL levels to any substantial degree (except for Rosuvastatin, which increases high-density lipoprotein (HDL) by 8% to 14%), nor do they alter the LDL particle size, from small dense LDL to a larger, less dangerous LDL particle size.3 These patients with low (or even normal) HDL levels do not avoid the attendant myocardial damage.4 Low HDL levels are linked to an increased risk of coronary heart disease (CHD)1 in the Framingham Study, and even in patients with relatively normal LDL and HDL levels, a small LDL particle size5 (pattern type B) can cause significant events in 50% of patients,2 as in the Quebec Cardiovascular Study6,7 (which also showed that HDL2 particles contributed to the cardioprotective effects of high HDL-C levels more than HDL3 particles). Thus, to provide more protection against unwarranted myocardial events - thrombosis and occlusion - more attention should be devoted to increasing HDL levels and to modification of LDL particle size. Although atherosclerosis occurs due to abnormal lipids, the entire damaging process has three components:

  • dyslipoproteinemia;
  • the inflammatory component, or endothelial inflammation caused by endothelial dysfunction; and
  • the thrombotic event.

It is as a result of the high triglycerides and low HDL, along with a large lipid load, that the inflammatory reaction occurs.

Atherosclerosis

It is well documented that reduced HDL-C levels are associated with an increased risk of coronary artery disease (CAD),8 while those patients whose HDL is increased after an event32 are afforded a partial protection against a second event. Intravenous infusion of HDL rapidly normalizes endothelium-dependent vasodilation by increasing nitric oxide (NO) bioavailability, and reduces the lipid load in the vascular wall. This may in part explain the protective effect of HDL9,10 from CHD and illustrates the potential therapeutic benefit of increasing HDL in patients at risk from atherosclerosis.12

Inflammation and HDL

The inflammatory response in cardiovascular disease and the participation of the inflammatory mediators TNFa in the atherosclerotic process ending in plaque rupture,17 is well established. The vascular cytokines18 along with the selectins, the interleukin family, recruiting matrix metalloproteinase (MMP) family of cytokines with growth and transforming factors is also well established. This ultimately leads to an increase in C-reactive protein (CRP) and LP-PLA215, both important markers of cardiovascular risk and events. CRP, lipoprotein-associated phospholipase A2 (A2LP-PLA2) added to HDL2b in patients with insulin resistance (IR) may refine the predictive value for cardiovascular risk and events.

There are several aspects to the mechanisms of inflammation pertaining to HDL:

  • Surface endothelial vascular inflammation that promote the initial phases of local vascular inflammation that become subendothelial occur more frequently with low HDL even when LDL is relatively normal,21 excluding the presence of small dense (SD)-LDL.
  • Cellular changes that promote the efflux of cholesterol from macrophages,19 aided by Scavenger receptor (SR) B1, prevent or reduce the macrophage content of cholesterol, are hindered during MMP reactions.24 Its consequent effects that later result in the familiar high-sensitivity (hs) CRP are increased when HDL is low.20
  • Platelet activation often associated with high triglycerides and low HDL are a cause for global platelet activation,25 with rapid translocation of P-selectin platelet alpha-granules. Intracellular cyclic adenosine monophosphate (cAMP) is a potent inhibitory pathway that results in global down-regulation of platelet activation. cAMP promotes the formation of apolipoprotein (Apo) A1 through ATP-binding cassette, sub-family (ABCA1), and is reduced in the absence of an adequate level of HDL often due to the excessive formation of phosphodiesterases (PDE) 3, 4, and 5s.
  • The upregulation of inflammatory adhesion molecules which induce CRP is completely prevented by in vitro treatment that HDL. HDL-C with a high Apo A1 can exert anti-inflammatory effects on the vasculature.22 HDLs ability to return the process to normal in the presence of adequate or normalized HDL.23
  • Lastly, there is the oxidative-based inflammation incited by formation oxLDL-C with macrophage oxidative foam cell formation - in such instances an adequate HDL acts as an inhibiting factor.24

 

Thrombosis and HDL

Triglyceride-rich lipoproteins and oxLDL are associated with a procoagulant profile and contribute to a prothrombotic risk via enhanced platelet reactivity25,30 and an associated increased plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis is also significantly reduced.31 High HDL has an anticoagulant effect through polymorphisms of paraoxonase (PON1) that inhibits the oxidation of LDL by reducing platelet thrombus formation30 and increasing pro-fibrinolytic properties. High levels of D-dimer commonly present in patients with low HDL, low levels of ApoA-I and high ApoB were independently associated with recurrent coronary events.31

The resulting inflammatory instability, causing a thinning of the cap over the plaque with its subsequent rupture,17 combined with an increase in thrombogenicity that creates most of the eventual risk of thrombosis and occlusion. Inflammation is one of the most prominent single factors that eventually trigger the occurrence of an occlusive coronary, carotid, or peripheral vascular event. The resulting tissue damage ultimately leads to loss of organ function.

Reverse Cholesterol Transport

Free cholesterol is normally distributed to all cells since it is involved in the formation of various important components of the cell structure and function, including the formation of steroids and hormones. HDL is responsible for the process of bringing either the excess cholesterol (redistribution of cholesterol) or the unused cholesterol from the various parts of the body back to the liver, 50% of the cholesterol is recycled via reverse cholesterol transport, and the remaining 50% is recycled through the cholesteryl ester transfer protein (CETP) pathway. Approximately 50% of the HDL is involved in reverse cholesterol transport (RCT), while the rest is involved in reducing inflammation, thrombosis, influencing cellular cardiac and vascular remodeling, and improving endothelial function, as well as vasodilatation and the production of NO. Free Apo A1 potentiates these effects, preserving the presence of prostacyclin and cAMP levels, which are important resident vasodilators.39

Apo A1, the anti-atherogenic apolipoprotein, provides 70% of the protein content of HDL, forming the majority of the attachments to the outer shell, which serve as acceptors for cholesterol released from the cells. Its synthesis is required for HDL production and is involved in the esterification (binding) of free cholesterol on HDL42 and later the maturation of HDL by lecithin:cholesterol acyltransferase (LCAT).70 Apo A1 activates the important transfer protein LCAT, which is vital to the endothelial surface. ApoA-I, synthesized by the liver hepatocyte, interacts with cellular ATP-binding cassette transporter (ABCA1),40 which mediates the first step of reverse cholesterol transport, which is then secreted into the plasma as a lipid-poor particle, forming HDL2b particles, a cholesterol acceptor similar to pre-beta- HDL. Removal of excess cholesterol from macrophages and the vascular wall occurs in a similar manner.41 ABCA1 is also a key regulator of the plasma Apo A1 and HDL pool size.

Through transfer by CETP, a cholesteryl ester core is added, and those including cholesterol from ApoB are returned to the liver mediated by SR-BI, thus controlling the selective transfer of cholesteryl ester from HDL to hepatocyte and other cells.

Cholesterol is taken up selectively to be excreted through two possible pathways: through the liver and then to bile promoted by phospholipid transfer protein (PLTP), and through the transfer of cholesteryl esters from HDL to apoB-containing lipoproteins in exchange for triglycerides, mediated by CETP.

SR B144 controls the cholesterol and CE between cells, while CETP controls CE transfer and triglyceride exchange with triglyceride-rich lipoproteins enrichment, resulting in a smaller, denser LDL. High CETP and free fatty acid (FFA) tend to be detrimental to maintaining a high level of HDL and a larger HDL2b pool.

There is an inverse correlation between plasma adiponectin and tumor necrosis factor (TNF)-α, C-reactive protein, and visceral adipose tissue. Adiponectin decreases, with increasing IR or weight gain, increasing CETP early in the metabolic syndrome even prior to adiposity in young hypertensives, thus HDL decreases, which in turn decreases the lipolysis directed toward LPL69 and the Apo C II donation by HDL, resulting in an increase in endothelial lipase,71 an important factor in the causation of instability at the endothelial surface and degradation of HDL.

The lipase system is mainly LPL,69 endothelial71 and hepatic lipase, the latter significantly enhances HDL and CE uptake, ultimately raising triglycerides and reducing HDL, producing a smaller denser HDL3b and c subclass.

HDL Particle Size and FFA

The typical dyslipidemia associated with insulin reisitance (IR) and type 2 diabetes commonly increases the efflux of FFA from adipose tissue with impaired muscle utilization of FFA, which causes an elevated FFA in these individuals.65 It has been postulated to be the cause behind pancreatic lipotoxicity, with loss of first phase insulin secretion in the metabolic syndrome and diabetes and later pancreatic beta cell failure. It is the elevated FFA in the presence of high triglycerides and low HDL that compound the LDL and SD-LDL66 oxidative potential.

Cardiovascular Effects of HDL

Elevated HDL-C or ApoA-I, are protective to the endothelial surface against endothelial dysfunction and CAD. The interaction between the lipoproteins endothelial surface46 and cardiovascular tissues involves activation of cellular NO signaling pathways, endothelialen NO-Synthase endothelial nitric oxide synthase (eNOS),47 protacycline with regulation of genes or the modification of proteins involved in vasomotor function, platelet activation, thrombosis and thrombolysis, cell adhesion, apoptosis and cell proliferation, and cellular cholesterol homeostasis. Adiponectin shares in these functions by raising HDL-C through its receptor T-cadherin, which resides on the endothelium as well as the muscle.

The independent association between low HDL-C and subclinical left ventricular (LV) systolic dysfunction, and a lower cardiac index, which unfavorably modifies LV structure and diastolic function75, is often a higher left ventricular mass and index, and a lower pulse pressure/stroke index. Hypertensive metabolic syndrome patients often have early diastolic LV abnormalities. A frequent association with obstructive sleep apnea (OSA) with a higher incidence of microvoltage T wave alterans (M-TWA) and QT and QTc dispersion during periods of oxygen desaturation is not uncommon.

Ischemic heart disease with unstable angina and acute coronary syndrome (ACS) risk are more closely associated with the low HDL-C/high triglyceride syndrome than with increased LDL or total cholesterol levels. Rupture of a lipid-laden unstable endothelial plaque that is Ôëñ50% occlusive appears to be a key event.

Cardiovascular Risk at Various HDL Levels

ATP III guidelines set a low HDL level below 40mg/dl to be a much higher risk of cardiovascular events.They also suggest that higher HDL is better without establishing a treatment goal for HDL. IR HDL levels below 31.5mg/dl increase that risk by an added 32%, while HDL <31.5mg/dl without IR increases the relative risk by only 5%.This added risk with IR is due to the common association of low absolute level of HDL-C with a smaller HDL3 particle size, or a greater proportion of HDL3 to HDL2b (the latter contains a larger proportion of Apo A1).

Management and Therapy for Low HDL

Reducing risk factors is vital and can produce dramatic results as shown by numerous investigators in many trials, some conferring 68% morbidity and mortality reductions when there is a concomitant HDL-C increase with reduction in both LDL and triglycerides, and improvement in particle size. Raising HDL-C to 50-60mg/dl from a level of <35mg/dl usually reduces the non HDL-C by at least 40-80 points, if the triglycerides are concomitantly elevated at baseline.

Recent clinical trials such as the veterans affairs high density lipoprotein cholesterol intervention trial (VA-HIT)8 and the Quebec Cardiovascular Trial in patients with CAD indicate that increasing previously low levels of HDL-C significantly reduces the cumulative occurrence of cardiovascular and cerebrovascular events in patients whose only lipid abnormality was low HDL. These data provide a compelling scientific basis for a more targeted and segmental approach to managing patients with dyslipidemia, where decreasing elevated levels of LDL-C and increasing low levels of HDL-C should comprise dual targets of pharmacotherapy.

Niacin, Fenofibrates and Peroxisome Proliferator Receptors

Current therapeutic strategies to raise HDL-C and improve the particle distribution is through combination therapy, which improves the HDL increase beyond the 30% limit for monotherapy. This may be achieved by use of nicotinic acid that predominantly stimulates LPL80 through the adipocyte receptor HM 74, a specific G-protein-coupled receptor, where it reduces triglycerides and Apo-B containing lipoproteins mainly through:

  • decreasing fatty acid mobilization from adipose tissue triglyceride stores; and
  • inhibiting hepatocyte diacylglycerol acyltransferase (DAG2) and triglyceride81 synthesis with reduction in VLDL,Apo B and triglyceride production in the liver and increased catabolism, leading to increased intracellular Apo B degradation and subsequent decreased secretion of VLDL and LDL particles. It raises HDL by decreasing the fractional catabolic rate of Apo AI without affecting the synthetic rates, while selectively increasing the plasma levels of Apo-AI subfraction HDL2b (HDL subfraction without apo AII), a cardioprotective subfraction of HDL in patients with low HDL.82

Fenofibrates have a major function of peroxisome proliferator receptors (PPAR)yα agonist effect,83 which reduces the triglyceride-rich lipoproteins.84 They also increase Apo AI production and lipoprotein lipase activity, and reduce Apo CIII, thus increasing HDL.

PPARyα increase Adiponectin,86 thus raise HDL, in addition to improving glucose transport and utilization, and reducing FFA. All three classes of drugs improve the particle size from small dense to the larger type A. A novel approach that has been very successful, which has been tried clinically in several hundred patients, is a combination of niacin, fenofibrate and a PPARyα agonist. These can increase HDL by 81%89 or more by combining all three drugs in lower than the usual upper limit therapeutic doses, in patients with a baseline HDL below 40mg/dl.90

Combination statin and niacin88 or statin and fenofibrate87 have been used clinically with success and advantages over monotherapy. With statin combination therapy, first consideration should be given to less hepatotoxic and hydrophilic statins used as at lower dosage. In order to meet additional therapy goals, added colesevelam and ezitimibe can raise HDL-C by an additional 10%, and can reduce inflammation by an additional 20% to 35%, representing a substantial risk reduction.

The new battle ground against myocardial damage is through modulation of HDL-C and Apo A1 metabolism. By reduction in cholesterol content, change in LDL and HDL particle size, (modified by the Apo A1 pool), reduction in CE content and triglyceride transfer eventually modify the lipid profile. The key factor is overall reduction in FFA accumulation eight hours after meals, so as to reduce endothelial lipase,71 a key factor in the catabolic destruction of HDL-C.

Conclusion

HDLs are the Multifunctional Vanguards of the Cardiovascular System

A cluster of interrelated plasma lipid and lipoprotein abnormalities associated with alterations in HDL and HDL subfraction metabolism contributes to the risk of atherosclerosis and cardiovascular events in patients with IR and type 2 diabetes. HDL levels control atherogenesis, vascular inflammation, endothelial function, and thrombogenicity. Features of the HDL dyslipidemia can be improved by a variety of therapeutic combinations and lifestyle changes including weight loss, and or exercise.The alteration in particle size of both HDL and LDL contribute to events and progression of disease, therefore therapy that ameliorates particle size enhances the effectiveness of the therapeutic modality.

References

  1. Enzyme on HDL protective against CHD, may be modifiable target for preventing coronary events HeartWire News; May 19, 2003
  2. Mingpeng S and Zongli W, "The protective role of high-density lipoproteins in atherosclerosis", Exp. Gerontol. (1999), Jul; 34 (4): pp. 539-548.
    Crossref | PubMed
  3. Campos H, Genest J J Jr, Blijlevens E, McNamara J R, Jenner J L, Ordovas J M,Wilson P W F and Schaefer EJ,"Low density Lipoprotein particle size and coronary artery disease", Arterioscler.Thromb.Vasc. Biol. (1992), 12: pp. 187-195.
    Crossref
  4. Barter P, Kastelein J and Nunn A, "High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions", Atherosclerosis (2003) Jun; 168 (2): pp. 195-211.
    Crossref | PubMed
  5. Coresh J, Kwiterovich P O Jr, Smith H H, Bachorik P S, "Association of plasma triglyceride concentration and LDL particle diameter,density and chemicalcomposition with premature coronary artery disease in men and women", J. Lipid. Res. (1993), 34: pp. 1,687-1,689.
    PubMed
  6. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, Dagenais G R and Despres J P,"Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study", Arch. Intern. Med. (2001), Dec 10-24; 161 (22): pp. 2,685-2,692.
    Crossref | PubMed
  7. Despres J P, Lemieux I, Dagenais GR, et al., "HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study", Atherosclerosis (Ireland), Dec (2000), 153 (2) pp. 263-272.
    Crossref | PubMed
  8. Meyers C D and Kashyap M L,"Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection",Curr. Opin. Cardiol. (2004) Jul;19 (4): pp. 366-373.
    Crossref | PubMed
  9. Rubins H, Robins S J, Collins D, Fye C L, Anderson J W, Elam M B, Faas F H, Linares E, Schaefer E J, Schectman G,Wilt T J and Wittes J, "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol",Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N. Engl. J. Med. (1999), 341: pp. 410-418.
    8. Miller N E and Miller G J, "High-density lipoprotein and atherosclerosis", Lancet (1975), 1: p. 1,033.
    9. Meyers C D and Kashyap M L,"Pharmacologic elevation of high-density lipoproteins:recent insights on mechanism of action and atherosclerosis protection", Curr. Opin. Cardiol. (2004) Jul;19 (4): pp. 366-373.
    Crossref | PubMed
  10. Price M J and Shah P K,"New strategies in managing and preventing atherosclerosis: focus on HDL", Rev. Cardiovasc. Med. (2002), Summer; 3 (3): pp. 129-137.
    PubMed
  11. Plump A S, Scott C J and Breslow J L, "Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse", Proc. Natl. Acad. Sci. USA (1994), 91: pp. 9,607-9,611.
    Crossref | PubMed
  12. Rader D J, "High-density lipoproteins and atherosclerosis", Am. J. Cardiol. (2002) Oct 17; 90 (8A): pp. 62i-70i.
    Crossref | PubMed
  13. Aikawa M, Rabkin E, Okada Y,Voglic S J, Clinton S K, Brinckerhoff C E, Sukhova G K and Libby P,"Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization [see comments]", Circulation (1998), 97: pp. 2,433-2,444.
    Crossref | PubMed
  14. Ansell B J, Navab M, Hama S, et al.,"Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment", Circulation (2003), Nov 24; 108: pp. 2,751-2,756.
    Crossref | PubMed
  15. Ballantyne C M, Hoogeveen R C, Bang H, Coresh J, Folsom A R,Heiss G and Sharrett A R,"Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study" Circulation (2004), Feb 24;109 (7): pp. 837-842 (ISSN: 1524-4539).
    Crossref | PubMed
  16. Baker P W and Rye K A,"Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells", Curr. Opin. Lipidol. (2002), Jun; 13 (3): pp. 285-288 (ISSN: 0957-9672).
    Crossref | PubMed
  17. Forrester J S,"Prevention of plaque rupture:Anew paradigm of therapy", Ann. Intern. Med. (2002), 1379 (10): pp. 823-833.
    Crossref | PubMed
  18. Laura Calabresi; Monica Gomaraschi; Barbara Villa; Laura Omoboni; Camille Dmitrieff; Guido Franceschini "Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol(In both hyperlipidemic and normolipidemic patients)".
  19. Libby P, "Molecular bases of the acute coronary syndromes", Circulation (1995), 91: pp. 2,844-2,850, Oxidation.
    Crossref | PubMed
  20. Libby P "Inflammation in atherosclerosis", Nature (2002), 420 (6917): pp. 86-74.
    Crossref | PubMed
  21. Calabresi L, Gomaraschi M,Villa B, Omoboni L, Dmitrieff C and Franceschini G,"Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol", Arterioscler.Thromb.Vasc. Biol. (2002), Apr 1; 22 (4): pp. 656-661
    Crossref | PubMed
  22.  
  23. Spieker L E, Ruschitzka F, Luscher T F and Noll G, "HDL and inflammation in atherosclerosis", Curr. Drug Targets Immune Endocr.Metabol. Disord. (2004), Mar; 4 (1): pp. 51-57.
    Crossref | PubMed
  24. Sharma N, Desigan B, Ghosh S, Sanyal SN and Ganguly NK,"Majumdar Therole of oxidized HDL in monocyte/macrophage functions in the pathogenesis of atherosclerosis in Rhesus monkeys", Scand. J. Clin. Lab. Invest. (1999), May; 59 (3): pp. 215-225.
    Crossref | PubMed
  25. Naqvi T Z, Shah P K, Ivey PA, Molloy MD,Thomas AM, Panicker S,Ahmed A, Cercek B and Kaul S,"Evidence that highdensity lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation", Am. J. Cardiol. (1999), Nov 1; 84 (9): pp. 1,011-1,017, (ISSN: 0002-9149).
    Crossref | PubMed
  26. Anand S S,Yi Q, Gerstein H, Lonn E, Jacobs R,Vuksan V,Teo K, Davis B, Montague P and Yusuf S,"Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease", Circulation (2003), Jul 29; 108 (4): pp. 420-425 (ISSN: 1524-4539).
    Crossref | PubMed
  27. Cuchel M and Rader D J, "The role of high density lipoproteins in thrombosis", ScientificWorldJournal (2002), Jan 12; 2: pp. 89-95, (ISSN: 1537-744X).
    Crossref | PubMed
  28. Li D,Weng S,Yang B, Zander D S, Saldeen T, Nichols W W, Khan S and Mehta J L,"Inhibition of arterial thrombus formation by ApoA1Milano", Arterioscler.Thromb.Vasc. Biol. (1999), Feb;19 (2): pp. 378-383, (ISSN: 1079-5642).
    Crossref | PubMed
  29. Moss A J, Goldstein R E, Marder V J, Sparks C E, Oakes D, Greenberg H,Weiss H J, Zareba W, Brown M W, Liang C S, Lichstein E, Little W C, Gillespie J A,Van Voorhees L, Krone R J, Bodenheimer M M, Hochman J, Dwyer E M, Arora R, Marcus F I,Watelet L F and Case R B, "Thrombogenic factors and recurrent coronary events", Circulation (1999), May 18; 99 (19): pp. 2,517-2,522
    Crossref | PubMed
  30. Naqvi T Z, Shah P K, Ivey P A, Molloy M D,Thomas A M, Panicker S, Ahmed A, Cercek B and Kaul S, "Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation", Am. J. Cardiol. (1999), Nov 1; 84 (9): pp. 1,011-1,017 (ISSN: 0002-9149).
    Crossref | PubMed
  31. Puccetti L, Bruni F, Pasqui A L, Pastorelli M, Bova G, Cercignani M, Palazzuoli A and Auteri A, "Dyslipidemias and fibrinolysis", Ital. Heart J. (2002), Oct; 3 (10): pp. 579-586.
    PubMed
  32. Moss A J, Goldstein R E, Marder V J, Sparks C E, Oakes D, Greenberg H,Weiss H J, Zareba W, Brown M W, Liang C S, Lichstein E, Little W C, Gillespie J A,Van Voorhees L, Krone R J, Bodenheimer M M, Hochman J, Dwyer E M, Arora R, Marcus F I,Watelet L F and Case R B, "Thrombogenic factors and recurrent coronary events", Circulation (1999), May 18; 99 (19): pp. 2,517-2,522
    Crossref | PubMed
  33. Cheung M C,Wolfbauer G, Brown B G and Albers J J "Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease", Atherosclerosis (1999), Jan; 142 (1): pp. 201-205.
    Crossref | PubMed
  34. Bortnick A E, Favari E,Tao J Q, Francone O L, Reilly M, Zhang Y, Rothblat G H and Bates S R, "Identification and characterization of rodent ABCA1 in isolated type II pneumocytes", Am. J. Physiol. Lung Cell. Mol. Physiol. (2003), Oct; 285 (4): pp. L869-L878
    Crossref | PubMed
  35. hambenoit O, Hamon Y, Marguet D, et al.,"Specific docking of apolipoprotein A-I at the cell surface requires a functional ABCA1 transporter", J. Biol. Chem. (United States), Mar 30 (2001), 276 (13) pp. 9,955-9,960
    Crossref | PubMed
  36. Haidar B, Denis M, Krimbou L, Marcil M and Genest J, "cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts", J. Lipid. Res. (2002) Dec; 43 (12): pp. 2,087-2,094 (ISSN: 0022-2275).
    Crossref | PubMed
  37. Haidar B, Denis M, Marcil M, Krimbou L and Genest J, "Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter", J. Biol. Chem. (2004) Mar 12; 279 (11): pp. 9,963-9,969 (ISSN: 0021-9258).
    Crossref | PubMed
  38. Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L and Genest J, "Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1)", J. Biol. Chem. (2004) Feb 27; 279 (9): pp. 7,384-7,394
    Crossref | PubMed
  39. Lin G and Bornfeldt K E, "Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux", Biochem. Biophys. Res. Commun (2002) Jan 18; 290(2): pp. 663-669
    Crossref | PubMed
  40. Liu L, Bortnick A E, Nickel M, Dhanasekaran P, Subbaiah P V, Lund-Katz S, Rothblat G H and Phillips M C, "Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles", J. Biol. Chem. (2003) Oct 31; 278 (44): pp. 42,976-42,984.
    Crossref | PubMed
  41. Okuhira K,Tsujita M,Yamauchi Y, Abe-Dohmae S, Kato K, Handa T and Yokoyama S, "Potential involvement of dissociated apoA-I in the ABCA1-dependent cellular lipid release by HDL", J. Lipid. Res. (2004), Apr; 45 (4): pp. 645-652.
    Crossref | PubMed
  42. Oram J F and Lawn RM,"ABCA1.The gatekeeper for eliminating excess tissue cholesterol", J. Lipid. Res. (2001),Aug; 42 (8): pp. 1,173-1,179.
    PubMed
  43. Wang N and Tall A R,"Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux", Arterioscler.Thromb.Vasc. Biol. (2003), Jul 1; 23 (7): pp. 1,178-1,184 (ISSN: 1524-4636).
    Crossref | PubMed
  44. Acton S L, Kozarsky K F and Rigotti A,"The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?", Mol. Med. Today (1999), Dec; 5 (12): pp. 518-524.
    Crossref | PubMed
  45. Rigotti A,Trigatti B L, Penman M, Rayburn H, Herz J and Krieger M, "A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism", Proc. Natl. Acad. Sci. USA (1997), 94: pp. 12,610-12.615.
    Crossref | PubMed
  46. Spieker L E, Sudano I, Hurlimann D, Lerch P G, Lang M G, Binggeli C, Corti R, Ruschitzka F, Luscher T F and Noll G, "High-density lipoprotein restores endothelial function in hypercholesterolemic men", Circulation (2002), Mar 26; 105 (12): pp. 1,399-1,402.
    Crossref | PubMed
  47. Ramet M E, Ramet M, Lu Q, Nickerson M, Savolainen M J, Malzone A and Karas R H,"High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life", J. Am. Coll. Cardiol. (2003), Jun 18; 41 (12): pp. 2,288-2,297.
    Crossref | PubMed
  48. Calabresi L, Gomaraschi M and Franceschini G, "Endothelial protection by high-density lipoproteins: from bench to bedside", Arterioscler.Thromb.Vasc. Biol. (2003), Oct 1; 23 (10): pp. 1,724-1,731.
    Crossref | PubMed
  49. O'Connell B J and Genest J,"High-density lipoproteins and endothelial function", Circulation (2001), Oct 16; 104 (16): pp. 1,978-1,983.
    Crossref
  50.  
  51.  
  52.  
  53.  
  54.  
  55.  
  56.  
  57.  
  58.  
  59. CETP inhibitor markedly raises HDL: Benefit also seen in patients concomitantly receiving statins HeartWire Atherosclerosis; Apr 7, 2004.
  60. Brousseau M E, Schaefer E J,Wolfe M L, et al.,"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol", N. Engl. J. Med. (2004), Apr 8; 350 (15): pp. 1,505-1,515.
    Crossref | PubMed
  61. Clark R W, Sutfin T A, Ruggeri R B, et al., "Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib", Arterioscler.Thromb.Vasc. Biol. (2004), Mar; 24 (3): pp. 490-497.
    Crossref | PubMed
  62. de Vries R, Borggreve S E and Dullaart R P, "Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus", Clin. Lab. (2003); 49 (11-12): pp. 601-613.
    PubMed
  63. Yamamoto M and Katoh N, "Decreased apolipoprotein C-III concentration in the high-density lipoprotein fraction from calves inoculated with Pasteurella haemolytica and bovine herpes virus-1", J.Vet. Med. Sci. (2000) Jan; 62 (1): pp. 49-52.
    Crossref | PubMed
  64. Fredenrich A, "Role of Apolipoprotein CIII in triglyceride-rich lipoprotein metabolism", Diabetes Care (1998), 24: pp. 490-495.
    PubMed
  65. Westphal S, Gekeler G H, Dierkes J,Wieland H and Luley C, "A free fatty acid tolerance test identifies patients with coronary artery disease among individuals with a low conventional coronary risk profile", Heart Vessels (2002), Mar; 16 (3): pp. 79-85.
    Crossref | PubMed
  66. Pirro M, Mauriege P,Tchernof A, et al., "Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study", Atherosclerosis (Ireland), Feb 2002, 160 (2) pp. 377-384.
    Crossref | PubMed
  67. Andersen R V,Wittrup H H,Tybjaerg-J. Lipid Res. (1999), Jun; 40 (6): pp. 1,064-1,070, Hansen A, Steffensen R, Schnohr P and Nordestgaard B G, "Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study", J.Am. Coll. Cardiol. (2003), Jun 4; 41 (11): pp. 1,972-1,982
    Crossref | PubMed
  68. Ramsamy T A, Boucher J, Brown R J,Yao Z and Sparks D L,"HDL regulates the displacement of hepatic lipase from cell surface proteoglycans and the hydrolysis of VLDL triacylglycerol", J. Lipid Res. (2003), Apr; 44 (4): pp. 733-741.
    Crossref | PubMed
  69. Jin W, Marchadier D and Rader D J,"Lipases and HDL metabolism", Trends Endocrinol. Metab. (2002), May-Jun; 13 (4): pp. 174-178, (ISSN: 1043-2760).
    Crossref | PubMed
  70. Sakai N,Vaisman B L, Koch C A, Hoyt R F Jr, Meyn S M,Talley G D, Paiz J A, Brewer H B Jr and Santamarina-Fojo S, "Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAT) gene: generation of a new animal model for human LCAT deficiency", J. Biol. Chem. (1997), 272: pp. 7,506-7,510.
    Crossref | PubMed
  71. McCoy M G, Sun G S, Marchadier D, Maugeais C, Glick J M and Rader D J, "Characterization of the lipolytic activity of endothelial lipase", J. Lipid Res. (2002), Jun; 43 (6): pp. 921-929.
    PubMed
  72. McNamara J R, Jenner J L, Li Z,Wilson P W F and Schaefer E J,"Change in LDL particle size is associated with change in plasma triglyceride concentration", Arterioscler.Thromb.Vasc. Biol. (1992), 12: pp. 1,284-1,290.
    Crossref | PubMed
  73. Grundy S M,Vega G L, Otvos J D, Rainwater D L and Cohen J C,"Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men, Genetic and pharmacological evidence", J. Lipid Res. (1999), Feb; 40 (2): pp. 229-234.
    PubMed
  74. McNamara J R, Jenner J L, Li Z,Wilson P W F and Schaefer E J,"Change in LDL particle size is associated with change in plasma triglyceride concentration", Arterioscler.Thromb.Vasc. Biol. (1992), 12: pp. 1,284-1,290.
    Crossref | PubMed
  75. Horio T, Miyazato J, Kamide K,Takiuchi S and Kawano Y,"Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension", Am. J. Hypertens. (2003), Nov; 16 (11 Pt 1): pp. 938-944.
    Crossref | PubMed
  76. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F and Franceschini G,"High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release", Circ. Res. (2003), Feb 21; 92 (3): pp. 330-337
    Crossref | PubMed
  77. Oram J F and Lawn R M,"ABCA1.The gatekeeper for eliminating excess tissue cholesterol", J. Lipid Res. (2001),Aug; 42 (8): pp. 1,173-1,179.
    PubMed
  78. Ikeda T, Saito H,Tanno K, Shimizu H,Watanabe J, Ohnishi Y, Kasamaki Y and Ozawa Y,"T-Wave alternans as a predictor for sudden cardiac death after myocardial infarction", Am. J. Cardiol. (2002), 89: pp. 79-82.
    Crossref | PubMed
  79. Koeller J and Talbert R L, "Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk", Pharmacotherapy (2002), Oct; 22 (10): pp. 1,266-1,277, Meyers C D and Kashyap M L,"Pharmacologic elevation of highdensity lipoproteins: recent insights on mechanism of action and atherosclerosis protection", Curr. Opin. Cardiol. (2004), Jul; 19 (4): pp. 366-374.
    Crossref | PubMed
  80. Rosenson R S, "Antiatherothrombotic effects of nicotinic acid", Atherosclerosis (2003), Nov; 171 (1): pp. 87-96.
    Crossref | PubMed
  81. Kamanna V S and Kashyap M L,"Mechanism of action of niacin on lipoprotein metabolism", Curr.Atheroscler. Rep. (2000), 2: pp. 36-46.
    Crossref | PubMed
  82. Saareks V, Mucha I, Sievi E and Riutta A,"Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man", Pharmacol.Toxicol. (1999), Jun; 84 (6): pp. 274-280.
    Crossref | PubMed
  83. Sheperd J,"Mechanism of action of fibrates", Postgraduate Med. J. (1993), 69 (Suppl. 1) : pp. 534-541.
    Crossref
  84. Elisaf M, "Effects of fibrates on serum metabolic parameters", Curr. Med. Res. Opin. (2002), 18 (5): pp. 269-276 (ISSN: 0300-7995).
    Crossref | PubMed
  85. Davidson M H, "Combination therapy for dyslipidemia: Safety and regulatory considerations", Am. J. Cardiol. (2002), 90 (Suppl 10B): pp. 50K-60K.
    Crossref | PubMed
  86. Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, Baumstark M W, Krebs K,Wieland H and Marz W, "Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study", Diabetes Care (2003), Sep; 26 (9): pp. 2,588-2,594.
    Crossref | PubMed
  87. Athyros V G, Papgergiou A A, Athyrou V V, Dimitriadis D S and Kontopoulos A G, "Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia", Diabetes Care (2002), 25: pp. 1,198-1,202.
    Crossref | PubMed
  88. Duvall W L, Blazing M A, Saxena S and Guyton J R,"Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy", J. Cardiovasc. Risk (2002), Dec; 9 (6): pp. 339-347.
    Crossref | PubMed
  89. Tawakol R and King A B, "Marked HDL Cholesterol Benefit in Patients with Low HDL-C and Type 2 Diabetes or Impaired Glucose Tolerance with Combined Treatment of Pioglitazone and Low Dose Nicotinic Acid", Diabetes Care (Suppl 2004) In publication.
  90. Tawakol R, "Clinical trials for Nicotinic acid aspirin combination, with fenofibrate and Pioglitizone", (Letter to Gate Pharmaceutical and Teva USA,Trial).
Previous Volume Article Next Volume Article